West Family Investments’s CRISPR Therapeutics CRSP Stock Holding History

West Family Investments’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.69M	Hold	35,500	–	–	0.59%	27
2025 Q4	$1.86M	Hold	35,500	–	–	0.44%	35
2025 Q3	$2.3M	Hold	35,500	–	–	0.51%	31
2025 Q2	$49	Buy	+35,500	New	+$1.37M	﹤0.01%	367
2025 Q1	–	Sell	-35,500	Closed	-$1.4M	–	287
2024 Q4	$1.4M	Hold	35,500	–	–	0.49%	42
2024 Q3	$1.67M	Hold	35,500	–	–	0.57%	28
2024 Q2	$1.92M	Hold	35,500	–	–	0.57%	37
2024 Q1	$2.42M	Hold	35,500	–	–	0.75%	32
2023 Q4	$2.22M	Hold	35,500	–	–	0.75%	32
2023 Q3	$1.61M	Hold	35,500	–	–	0.56%	40
2023 Q2	$1.99M	Hold	35,500	–	–	0.77%	27
2023 Q1	$1.61M	Hold	35,500	–	–	0.64%	38
2022 Q4	$1.44M	Hold	35,500	–	–	0.49%	39
2022 Q3	$2.32M	Hold	35,500	–	–	0.97%	22
2022 Q2	$2.16M	Hold	35,500	–	–	0.85%	22
2022 Q1	$2.23M	Buy	+35,500	New	+$2.23M	0.63%	26

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

West Family Investments's CRSP Position: Q1 2026 in Review

West Family Investments held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 35,500 shares worth $1.69M. The position accounts for 0.59% of the portfolio, ranked #27.

West Family Investments first reported a position in CRSP in Q1 2022 and has held it in 16 quarters since. The position peaked at $2.42M in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

West Family Investments held 35,500 shares of CRISPR Therapeutics worth $1.69M as of Q1 2026.
West Family Investments left its CRISPR Therapeutics share count unchanged in Q1 2026.
CRISPR Therapeutics made up 0.59% of West Family Investments's portfolio in Q1 2026, its #27 holding.
West Family Investments first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 16 quarters since.
West Family Investments's CRISPR Therapeutics position peaked at $2.42M in Q1 2024.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on West Family Investments's 13F filing for Q1 2026, filed 7 May 2026.